Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
•
Scleroderma
•
Eosinophilic Fasciitis
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
When do you consider adding steroid sparing agents?
Related Questions
What considerations do you take when using prednisone in patients with systemic sclerosis?
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
How do you approach symptom control in a patient with diffuse cutaneous systemic sclerosis (dcSSc) and rapidly progressive skin disease?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
How do you envision incorporating CAR-T therapy into your clinical practice?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
What would be your recommendation for treatment of worsening lung disease in a patient with long-standing scleroderma after long-term mycophenolate therapy which is no longer an option due to side effect/intolerance?
